Advances in the treatment of myasthenia gravis (MG) have reduced mortality rates due to the disease and improved patients' quality of life. Nowadays, attending neurologists can choose among different treatment strategies for MG patients. An exhaustive revision of published data on the efficacy of ...
See Treatment and Medication for more detail. What is myasthenia gravis? Myasthenia gravis is an autoimmune disease that's categorized as a type II hypersensitivity that involves autoantibodies binding acetylcholine receptors on skeletal muscle cells. Courtesy of Osmosis.org (https://www.osmosis.org/)...
重症肌无力英文版书-myasthenia gravis-lwx.docx,Myasthenia gravis Obiectives 1. To grasp the clinical features, diagnosis and treatment of myasthenia gravis(MG) 2. To understand the pathogenesis, clinical subtypes of MG and subtype of myasthenic crisis and
Novel therapies in Myasthenia gravis The treatment of MG has evolved significantly with new therapeutic approaches targeting specific components of the immune system, offering more precision and potentially fewer side effects than traditional immunosuppressive therapies. Here, we explore novel therapies for ...
Juvenile myasthenia gravis in Norway: clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort. Eur. J. Paediatr. Neurol. 21, 707–714 (2017). Article CAS PubMed Google Scholar Evoli, A. et al. Myasthenia gravis with antibodies to MuSK: an update....
Patients with autoimmune myasthenia gravis (MG) should be further classified before initiating therapy, as treatment response varies for ocular versus generalised, early onset versus late onset, and acetylcholine receptor antibody positive versus MuSK antibody positive disease. Most patients need ...
The records of 142 patients with generalized autoimmune myasthenia gravis who had been treated with steroids as the single immunosuppressive agent, collected at regular intervals, were employed for a retrospective evaluation. The effectiveness of treatment was assessed after 24 months; the data from the...
Myasthenia gravis (MG) is a rare autoimmune disease that causes debilitating muscle weakness due to impaired neuromuscular transmission. Since most (about 80-90%) MG patients present autoantibodies against the acetylcholine receptor, standard medical therapy consists of symptomatic treatment with acetylcholin...
These specific subtypes may influence a patient’s disease presentation, prognosis, and treatment plan.SymptomsMuscle weakness and muscle fatigue are the hallmark symptoms of myasthenia gravis. These symptoms may come and go, and usually get worse with activity and other triggers. In most cases, ...
Treatment of myasthenia gravis: focus on pyridostigmine Clin Drug Investig, 31 (10) (2011), pp. 691-701 CrossrefView in ScopusGoogle Scholar 50. S Hoffmann, S Kohler, A Ziegler, A Meisel Glucocorticoids in myasthenia gravis—if, when, how, and how much? Acta Neurol Scand, 130 (4) (20...